Gunnar Nordvall
Overview
Explore the profile of Gunnar Nordvall including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
148
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nordvall G, Yan P, Agholme L, Lundkvist J, Sandin J, Biverstal H, et al.
J Pharmacol Exp Ther
. 2025 Mar;
392(4):103400.
PMID: 40054389
γ-Secretase modulators (GSMs) represent an emerging oral therapy for preventing and targeting Aβ-amyloidosis in Alzheimer disease. Aβ is a family of peptides of varying lengths where both the total and...
2.
Saturnino Guarino D, Miranda Azpiazu P, Sunnemark D, Elmore C, Bergare J, Artelsmair M, et al.
ACS Chem Neurosci
. 2024 Nov;
15(22):4210-4219.
PMID: 39528351
The accumulation of aggregated α-synuclein (α-syn) is a pathological hallmark of Parkinson's disease (PD) and other synucleinopathies. Here within, we report the in vitro characterization targeting site 2 of α-syn...
3.
Forsell P, Parrado Fernandez C, Nilsson B, Sandin J, Nordvall G, Segerdahl M
Pharmaceuticals (Basel)
. 2024 Aug;
17(8).
PMID: 39204102
Neurotrophins are important regulators of neuronal and non-neuronal functions. As such, the neurotrophins and their receptors, the tropomyosin receptor kinase (Trk) family of receptor tyrosine kinases, has attracted intense research...
4.
Dudley M, Peet N, Demeter D, Weintraub H, Ijzerman A, Nordvall G, et al.
Drug Dev Res
. 2024 Jan;
28(3):237-243.
PMID: 38239889
This symposium provided a forum for presentations by the relevant groups on ligand design and ligand binding on the adenosine A, receptor. Agreement appears to exist that the "N-C" model...
5.
Nordvall G, Lundkvist J, Sandin J
Front Mol Neurosci
. 2023 Nov;
16:1279740.
PMID: 37908487
Recent clinical data with three therapeutic anti-Aβ antibodies have demonstrated that removal of Aβ-amyloid plaques in early Alzheimer's disease (AD) can attenuate disease progression. This ground-breaking progress in AD medicine...
6.
Parrado Fernandez C, Juric S, Backlund M, Dahlstrom M, Madjid N, Lidell V, et al.
Int J Mol Sci
. 2023 Jul;
24(13).
PMID: 37446337
The introduction of anti-amyloid monoclonal antibodies against Alzheimer's disease (AD) is of high importance. However, even though treated patients show very little amyloid pathology, there is only a modest effect...
7.
Madjid N, Lidell V, Nordvall G, Lindskog M, Ogren S, Forsell P, et al.
Psychopharmacology (Berl)
. 2023 Jul;
240(8):1789-1804.
PMID: 37394539
Background: Major depressive disorder (MDD) is defined as a complex mental disorder which is characterized by a pervasive low mood and aversion to activity. Several types of neurotransmitter systems e.g....
8.
Nordvall G, Forsell P, Sandin J
Drug Discov Today
. 2022 Jul;
27(10):103318.
PMID: 35850433
Neurotrophins, such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), are small proteins expressed in the brain and peripheral tissues, which regulate several key aspects of neuronal function,...
9.
Weber T, Lundkvist J, Wanngren J, Kvartsberg H, Jin S, Larssen P, et al.
J Cell Mol Med
. 2021 Dec;
26(3):880-892.
PMID: 34931449
The aggregation of β-amyloid peptide 42 results in the formation of toxic oligomers and plaques, which plays a pivotal role in Alzheimer's disease pathogenesis. Aβ42 is one of several Aβ...
10.
Dahlstrom M, Madjid N, Nordvall G, Halldin M, Vazquez-Juarez E, Lindskog M, et al.
Cells
. 2021 Aug;
10(8).
PMID: 34440640
Alzheimer's disease (AD) is the most common neurodegenerative disorder and results in severe neurodegeneration and progressive cognitive decline. Neurotrophins are growth factors involved in the development and survival of neurons,...